A method for producing a polyurethane polymer comprises the steps of: (a) providing a polyol composition, the polyol composition comprising (i) a polyol, (ii) a polyethylenimine compound; and (iii) a bisulfite compound, (b) providing an isocyanate compound; (c) providing a catalyst; (d) combining and reacting the polyol composition, the isocyanate compound, and the catalyst to produce a polyurethane polymer.

Thermosetting resin compositions useful for liquid compression molding encapsulation of a reconfigured wafer are provided. The so-encapsulated molded wafer offers improved resistance to warpage, compared to reconfigured wafers encapsulated with known encapsulation materials.

This invention relates to polymer-based partially-open, hollow reservoirs in the nano-size to micro-size range that encapsulate an additive, which can be released from the reservoirs using specific event stimuli such as reduction-oxidation and voltage change, or at will, using the same stimuli. This invention also relates to method preparing such reservoirs, and for releasing the additive. This invention further relates to matrix that comprises such reservoirs and the method of preparing such matrix. This invention also relates to applications, for example in corrosion inhibition, lubrication, and adhesion, that benefit from using such a controlled release of an additive.

The embodiments described herein generally relate to methods and chemical compositions for coating substrates with a composition. In one embodiment, an adhesive composition is provided comprising a reaction product of a polyacid selected from the group consisting of an aromatic polyacid, an aliphatic polyacid, an aliphatic polyacid with an aromatic group, and combinations thereof, or a diglycidyl ether; and a polyamine; and one or more compounds selected from the group consisting of a branched aliphatic acid, a cyclic aliphatic acid with a cyclic aliphatic group, a linear aliphatic, and combinations thereof. The adhesive composition may be used to cover a substrate.

A hyperbranched polymer includes a hyperbranched, hydrophobic molecular core, respective low molecular weight polyethyleneimine chains attached to at least three branches of the hyperbranched, hydrophobic molecular core, and respective polyethylene glycol chains attached to at least two other branches of the hyperbranched, hydrophobic molecular core. Examples of the hyperbranched polymer may be used to form hyperbranched polyplexes, and may be included in DNA or RNA delivery systems.

Disclosed are nanoparticles comprising an end-modified poly(β-amino ester) and an additive that is a sugar or sugar derivative, such as a sugar, a sugar alcohol or chitosan. The nanoparticles may be used in any field where polymers have been found useful, including in medical fields, particularly in drug delivery. The polymers are useful in delivering a polynucleotide such as DNA, RNA or siRNA, a small molecule or a protein. Also disclosed are compositions comprising said nanoparticles and an active agent, methods for preparing said nanoparticles, said nanoparticles and compositions for use in medicine, and in vitro methods using said nanoparticles and compositions.

Disclosed are nanoparticles comprising an end-modified poly(β-amino ester) and an additive that is a sugar or sugar derivative, such as a sugar, a sugar alcohol or chitosan. The nanoparticles may be used in any field where polymers have been found useful, including in medical fields, particularly in drug delivery. The polymers are useful in delivering a polynucleotide such as DNA, RNA or siRNA, a small molecule or a protein. Also disclosed are compositions comprising said nanoparticles and an active agent, methods for preparing said nanoparticles, said nanoparticles and compositions for use in medicine, and in vitro methods using said nanoparticles and compositions.

The invention relates to a production process for di- and polyamines of the diphenylmethane series by the rearrangement of a condensation product of aniline and a methylene group-supplying agent preferably selected from the group consisting of aqueous formaldehyde solution, gaseous formaldehyde, para-formaldehyde, trioxane and mixtures thereof, wherein said condensation product is reacted in the presence of at least one silica-alumina catalyst, said catalyst having a surface area as determined by the BET method carried out according to ASTM D3663-03 (2015) of from 200 m.sup.2/g to 520 m.sup.2/g, preferably of from 350 m.sup.2/g to 495 m.sup.2/g, particularly preferably of from 400 m.sup.2/g to 490 m.sup.2/g, a molar ratio of silica/alumina on the catalyst surface of A, an overall (bulk) molar ratio of silica/alumina of C, and a quotient B=A/C;
said catalyst being characterised in that “low” A values (i.e. equal to or lower than 8.0) are combined with “high” B values (i.e. of from 1.50 to 3.00), and “high” A values (i.e. larger than 8.00, especially equal to or larger than 8.50) are combined with “low” B values (i.e. of from 0.15 to 1.40).

Described herein are substituted polyetheramines with a low melting point which are obtainable by condensation of at least two N-(hydroxyalkyl)amines to obtain a polyetheramine and subsequent reaction of at least one remaining hydroxy group and/or, if present, at least one secondary amino group of said polyetheramine with ethylene oxide and at least one further alkylene oxide to obtain a substituted polyetheramine. Uses of such substituted polyetheramines in fields of cosmetic formulations, as crude oil emulsion brakers, in pigment dispersions of ink jets, in electro paintings, or in cementitious compositions as well as methods wherein said substituted polyetheramines are used in said fields are described herein.

The invention relates to medicine, namely, to the solutions used for hemostasis. The hemostatic agent, which represents a polyammonia methanediamine chloride of the general formula

##STR00001##

where: n=1-20, m=1-10, at that n×m≧8.

The hemostatic agent may be applied in the form of a 0.01-10% aqueous solution. An aqueous solution of the preparation can be used for impregnation of materials used for bleeding arrest, suture material, bandaging material. The hemostatic agent may be used in the composition of a retraction cord, adhesive pastes, vaginal and rectal suppositories, creams, gels, as well as used with microchips that provide slow release of the preparation. The preparation can also be used in eye drops, eye ointments, and lubricants applied to the surface of the catheter. The drug can be used in endodontic treatment, may be injected into a polymer sealer for root canal obturation, as well as locally—by means of electrophoresis. The hemostatic agent may be used in conjunction with a gel based on aluminum sulphate or silver solution, and also with a polysaccharide haemostatic system. An efficient haemostatic preparation ensuring a significant analgetic effect is developed.